Treatment Overview

While there is no cure for juvenile idiopathic arthritis, the disease may eventually disappear in some children. Treatment for juvenile idiopathic arthritis is focused on preventing flare-ups and controlling the symptoms.

Types of Treatments

Treatment for juvenile idiopathic arthritis includes medications, physical therapy, and surgery.

Medications – Medications usedfor the treatment of juvenile idiopathic arthritis may include:

Non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen sodium

COX-2 inhibitors, such as celecoxib, which are used to reduce joint pain and inflammation

Disease-modifying antirheumatic drugs, such as methotrexate, to relieve joint pain and swelling when there is high risk of joint damage

Immunosuppressants, also called biologics, which targets the immune system to reduce inflammation and prevent joint damage. Immunotherapy drugs used for the treatment of juvenile idiopathic arthritis include:

  • Abatacept
  • Adalimumab
  • Anakinra
  • Canakinumab
  • Etanercept
  • Infliximab
  • Rituximab
  • Tocilizumab

Corticosteroids, such as prednisone, to control symptoms and inflammation of the heart lining, also called pericarditis

Other medications for the treatment of juvenile idiopathic arthritis may include:

  • Azathioprine
  • Cyclosporine
  • Hydroxychloroquine
  • Leflunomide
  • Sulfasalazine
  • Thalidomide

Physical therapy may be recommended for patients with juvenile idiopathic arthritis to maintain joint flexibility, range of motion, and muscle tone.

Protective devices – Protective devices, such as joint supports or splints, may needed by patients with juvenile idiopathic arthritis to protect joints and prevent joint damage.

Surgery – Some patients with severe juvenile idiopathic arthritis may need surgery to correct a joint abnormality caused by the disease.

Complementary and Alternative Therapies – Complementary and alternative treatments for juvenile idiopathic arthritis may include:

  • Acupuncture
  • Cognitive behavioral therapy
  • Gluten elimination diet
  • Foods and supplements, such as blueberries and blueberry juice, turmeric, and fish oil
  • Massage
  • Yoga

Be certain to discuss any alternative therapies with your child’s doctor before trying.

Some children with juvenile idiopathic arthritis may need nutritional counseling and regular eye exams.

Long-Term Follow Up

Ongoing, long-term follow-up is an essential part of treatment for patients with juvenile idiopathic arthritis to help prevent flare-ups and joint damage and to monitor treatment effectiveness.

Sources

This content was written by the MediFind Medical Team. Last updated: 6/9/2022

Juvenile Idiopathic Arthritis (JIA) Approved Drugs

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Juvenile Idiopathic Arthritis (JIA).

Found 23 Approved Drugs for Juvenile Idiopathic Arthritis (JIA)

Tocilizumab

Brand Names
Actemra ACTPen, Tofidence, Actemra, Tyenne, Avtozma

Tocilizumab

Brand Names
Actemra ACTPen, Tofidence, Actemra, Tyenne, Avtozma
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 08, 2010
Classification: Interleukin-6 Receptor Antagonist
TYENNE ® (tocilizumab-aazg) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA).

Enbrel

Generic Name
Etanercept

Enbrel

Generic Name
Etanercept
Form: Solution
Method of administration: Subcutaneous
FDA approval date: June 07, 2019
Classification: Tumor Necrosis Factor Blocker
Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA).

Adalimumab

Brand Names
Amjevita, Yuflyma, Adalimumab-aacf, Yusimry, Humira, Hyrimoz, Hadlima

Adalimumab

Brand Names
Amjevita, Yuflyma, Adalimumab-aacf, Yusimry, Humira, Hyrimoz, Hadlima
Form: Injection, Kit, Solution
Method of administration: Subcutaneous
FDA approval date: December 31, 2002
Classification: Tumor Necrosis Factor Blocker
Plaque Psoriasis HYRIMOZ is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HYRIMOZ should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. Ulcerative Colitis HYRIMOZ is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF-blockers [see Clinical Studies (1. HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: Rheumatoid Arthritis (RA).

Adalimumab-FKJP

Brand Names
HULIO, Adalimumab

Adalimumab-FKJP

Brand Names
HULIO, Adalimumab
Form: Kit
FDA approval date: July 01, 2023
Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA).

Orencia

Generic Name
Abatacept

Orencia

Generic Name
Abatacept
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 01, 2009
Classification: Selective T Cell Costimulation Modulator
ORENCIA is a selective T cell costimulation modulator indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Showing 1-5 of 23
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances